Health Compass

The U.S. FDA approved the first nonprescription fixed-dose combination of acetaminophen and naproxen sodium for up to 12-hour pain relief.

Acetaminophen and naproxen work differently. Acetaminophen reduces pain and fever, while naproxen is a nonsteroidal anti-inflammatory drug, or NSAID, that can reduce pain and inflammation. Combining them in a single product may offer longer-lasting relief for some types of temporary pain.

Over-the-counter availability does not mean the medicine is risk-free. Too much acetaminophen can cause serious liver injury, while naproxen and other NSAIDs can increase the risk of stomach bleeding, kidney problems, and cardiovascular complications in some people.

Consumers should read the label carefully and avoid accidentally taking additional medicines containing the same ingredients. People with liver disease, kidney disease, ulcers, blood-thinner use, pregnancy, or other relevant conditions should ask a clinician or pharmacist before use.

Careful label reading remains especially important for safe use.

The U.S. FDA has approved Imaavy, or nipocalimab-aahu, as the first drug specifically approved for warm autoimmune hemolytic anemia, a rare condition in which the immune system attacks the body’s own red blood cells.

In warm autoimmune hemolytic anemia, autoantibodies bind to red blood cells and accelerate their destruction. This can cause anemia, fatigue, shortness of breath, jaundice, rapid heart rate, and other complications.

Nipocalimab targets the neonatal Fc receptor, or FcRn, a pathway involved in recycling IgG antibodies. By reducing levels of disease-causing IgG, the therapy is designed to lessen immune-mediated red-blood-cell destruction.

A first approved therapy can be a major milestone for a rare disease, but treatment still needs to be individualized. Clinicians consider the severity of anemia, previous therapies, transfusion needs, infection risk, and other medical conditions.

Patients should discuss dosing, monitoring, adverse effects, and alternative treatments with a hematologist.

The U.S. FDA has approved Tivicay PD, a dispersible formulation of dolutegravir, for HIV treatment in newborns, expanding antiretroviral options for some of the youngest patients.

Treating HIV early in life is critical because the virus can reproduce rapidly and damage the developing immune system. Newborn treatment also requires very precise dosing based on age, weight, organ function, and other medicines.

Dolutegravir is an integrase inhibitor, which means it blocks an enzyme HIV needs to insert its genetic material into human cells. Dispersible formulations can make treatment more practical for infants who cannot swallow conventional tablets.

The approval does not replace prevention strategies that reduce transmission during pregnancy, delivery, and breastfeeding. It provides another treatment option when neonatal HIV infection is diagnosed or strongly suspected under specialist care.

Families should work closely with pediatric HIV clinicians because dosing and follow-up can change quickly as an infant grows.

The U.S. FDA has approved Stelara, or ustekinumab, for pediatric ulcerative colitis, expanding treatment options for children living with this chronic inflammatory bowel disease.

Ulcerative colitis causes inflammation and ulcers in the lining of the large intestine. Symptoms can include diarrhea, blood in the stool, abdominal pain, urgency, fatigue, and problems with growth or nutrition in younger patients.

Stelara is a biologic medicine that targets the IL-12 and IL-23 immune pathways. It has already been used in several immune-mediated diseases in adults and in some pediatric indications. The new approval provides another option when clinicians are deciding how best to control intestinal inflammation and support long-term development.

Treatment plans in children need careful monitoring because growth, infection risk, vaccination status, nutrition, and school or daily functioning all matter.

Parents should discuss the approved age range, dosing, potential adverse effects, and alternative therapies with a pediatric gastroenterologist.

The U.S. FDA approved Besremi, or ropeginterferon alfa-2b-njft, for essential thrombocythemia, a chronic blood disorder in which the bone marrow produces too many platelets.

Too many platelets can increase the risk of blood clots, which may lead to complications such as stroke, heart attack, or other circulation problems. Some people can also experience unusual bleeding, headaches, vision changes, or burning pain in the hands and feet.

Essential thrombocythemia is usually managed according to a patient’s clotting risk, age, symptoms, blood counts, mutation status, and other medical conditions. Treatment may include low-dose aspirin when appropriate and medicines that reduce platelet production.

Besremi is an interferon-based therapy that affects blood-cell production and immune signaling. Its approval expands the range of disease-directed treatment options.

Patients should discuss the expected benefits, side effects, monitoring requirements, and alternatives with a hematologist. Regular blood counts and clinical follow-up remain important even when treatment is working.

The U.S. FDA approved Pasatru, or garetosmab-grts, for fibrodysplasia ossificans progressiva, a rare genetic disorder that causes abnormal bone to form in muscles and other soft tissues.

The condition, often called FOP, can progressively restrict movement as episodes of inflammation lead to new bone formation outside the normal skeleton. Even minor injuries or unnecessary procedures can sometimes trigger flare-ups, making medical management especially complex.

Pasatru is designed to target a biological pathway involved in abnormal bone formation. The FDA listed the medicine as the second approved treatment for FOP, expanding options for people living with a condition that previously had very limited disease-modifying therapies.

A new approval does not remove the need for specialized care. Patients may require coordinated management across genetics, orthopedics, rehabilitation, pain care, and other specialties.

Treatment decisions should consider age, disease activity, potential adverse effects, and the full prescribing information. People with FOP should avoid unnecessary procedures unless discussed with clinicians experienced in the condition.

An experimental blood test showed promise for detecting high-risk colore**al lesions before they had progressed to cancer, Reuters reported in August.

Finding advanced precancerous lesions is especially important because removing them can prevent some colore**al cancers from developing. Current screening options include colonoscopy, stool-based tests, and other methods, each with different strengths and limitations.

A blood test could potentially make screening easier for some people, especially those who avoid colonoscopy or stool testing. However, an experimental test is not yet a substitute for established screening. Researchers still need to confirm accuracy, false-positive rates, false-negative rates, performance across diverse populations, and whether use of the test actually improves health outcomes.

People should continue following recommended colore**al-cancer screening schedules based on age, family history, symptoms, and personal risk.

Anyone with concerning symptoms such as persistent re**al bleeding, unexplained iron-deficiency anemia, or major bowel-habit changes should seek medical evaluation rather than waiting for routine screening.
**alCancer

Moderna and Merck reported that a personalized mRNA cancer vaccine, used with pembrolizumab, reduced the risk of melanoma recurrence or spread in a large late-stage trial, according to Reuters.

Unlike infectious-disease vaccines, this treatment is designed individually from a patient’s tumor. Researchers identify tumor-specific mutations and create an mRNA vaccine intended to teach the immune system to recognize those cancer-related targets. Pembrolizumab is an immune checkpoint inhibitor that can help T cells remain active against cancer.

A successful Phase 3 study is an important milestone because it provides stronger evidence than earlier trials. However, full results, safety details, follow-up duration, and regulatory review still matter before a new treatment can become standard care.

Personalized cancer vaccines also involve complex manufacturing and may not be appropriate for every melanoma patient.

The U.S. FDA has approved Eli Lilly’s Mounjaro, or tirzepatide, to reduce cardiovascular risk in certain adults with type 2 diabetes, Reuters reported in late August.

People with type 2 diabetes have a higher risk of heart attack, stroke, and other cardiovascular complications. Treatments that improve blood glucose while also reducing cardiovascular risk can therefore have broader clinical value than glucose control alone.

Tirzepatide acts on the GIP and GLP-1 hormone pathways. It is already widely used in diabetes care, and related formulations are also used for chronic weight management. The new cardiovascular indication is specific to the population and evidence reviewed by the FDA.

As with other incretin-based medicines, treatment should be individualized. Side effects, kidney or gastrointestinal issues, other medications, blood-sugar goals, and overall cardiovascular risk all matter.

Patients should not start, stop, or change tirzepatide without medical guidance. The official prescribing information should be reviewed for the exact indication, warnings, and recommended use.

The U.S. FDA has approved updated COVID-19 vaccines for the 2026–27 season from Moderna, Novavax-Sanofi, and Pfizer-BioNTech, following recommendations that the formulations target the dominant XFG variant.

Updated vaccines are designed to better match circulating forms of the virus as SARS-CoV-2 continues to evolve. The goal is not to guarantee that a vaccinated person will never become infected, but to improve immune recognition of currently circulating variants and reduce the risk of severe illness.

Eligibility and recommended timing can depend on age, previous vaccination, underlying health conditions, and public-health guidance. People who are older, immunocompromised, pregnant, or living with chronic medical conditions may have different recommendations than healthy younger adults.

Anyone with questions about which product or timing is appropriate should check the latest CDC guidance or speak with a healthcare professional.

The FDA’s action concerns updated seasonal formulations; recommendations may continue to change as surveillance data evolve.